高盛：药明康德-2025 年中国医疗企业日 -关键要点

We hosted WuXi XDC's Head of IR & PR with investors on Jun 24 at our China Healthcare Corporate Day 2025. Bottom line: mgmt reiterated 1) high visibility of FY25 revenue growth guidance of over 35% y/y, backed with strong client demand in ADC development, particularly from emerging China Biotech companies; 2) technological leadership in ADC and bio-conjugates, e.g. diversified technology platform for DAR, payload, linker, etc., and the advantage of new molecule development; 3) on-track capacity expansion wi ...